Neurocrine Biosciences (NBIX) Reports Q3 Loss of $0.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Neurocrine Bio. (NBIX) PT Raised to $90 at Cowen as Ingrezza Blows Past Expectations
November 2, 2017 6:26 AM EDTCowen analyst Phil Nadeau raised his price target on Neurocrine Bio. (NASDAQ: NBIX) to $90.00 (from $65.00) while maintaining an Outperform rating following Q3 Ingrezza sales of $45.8MM, over 4x consensus of $10.8MME, and largely reflected end-user demand.
"While Q4 will be impacted by... More
